abs387.txt	background		aspirin	may	reduce	the	risk	of	several	types	cancer	objectives	to	evaluate	if	folic	acid	is	associated	with	basal	cellcarcinoma	(bcc)	methods	bcc	incidence	was	evaluated	in	a	randomized	double-blind	placebo-controlled	clinical	trial	(81	mg	daily	or	325	for	~3years)	and/or	(1	~6	years)	prevention	ofcolorectal	adenomas	among	1121	participants	previous	adenoma	wasconfirmed	by	blinded	review	pathology	reports	results	one	hundred	and	four	958	non-hispanic	white	werediagnosed	over	median	follow-up	13·5	years	cumulative	ofbcc	12%	[95%	confidence	interval	(ci)	7-17]	placebo	16%	(95%	ci	11-21)for	81	15%	10-20)	[hazardratio	(hr)	any	1·45	0·93-2·26)	hr	1·57	(95%ci	0·96-2·56)	1·33	0·80-2·20)]	higherwith	use	those	without	skin	but	lower	usein	(pinteraction	=	0·02	pinteraction	0·03	daily)	supplementation	wasunrelated	(hr	0·85	95%	0·57-1·27)	conclusions	neither	nor	treatment	had	statisticallysignificant	effect	on	subgroup	analysis	suggested	thatchemopreventive	effects	nonsteroidal	anti-inflammatory	drugs	be	specificto	at	high
